FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 10/2024”.
The Monitor is a month-to-month revealed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the top of October 2024 we recognized the next present VC traits in Europe:
- Complete Healthcare & Life Sciences funding reached EUR 31,125m
- Biotech/Pharma obtained 54% of the full funding quantity (EUR 16,712m) with oncology being the main indication (28%)
- In October Treeline Biosciences secured the very best transaction quantity with EUR 381m, adopted by Kailera Therapeutics with EUR 360m and Alpha-9 Oncology with EUR 159m
- RA Capital Administration (United States) is probably the most lively investor (by deal quantity in 2024), adopted by ARCH Enterprise Companions (United States) and Atlas Enterprise (United States)
To entry the total report, please click on right here.
